Search
Alvespimycin
go.drugbank.com/drugs/DB12442InvestigationalIt has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent. … In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic liability, lower plasma protein binding, increased water solubility
Zanthoxylum clava-herculis whole
go.drugbank.com/drugs/DB14353ApprovedZanthoxylum clava-herculis whole is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Etofamide
go.drugbank.com/drugs/DB13258ApprovedEtofamide is used as an antiamoebic agent. Etofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued [L5617].
Triethylhexanoin
go.drugbank.com/drugs/DB14102InvestigationalTriethylhexanoin is an ingredient of cosmetic products as a fragrant solvent.
Categories: Compounds used in a research, industrial, or household settingVeglin
go.drugbank.com/drugs/DB05890ExperimentalVeglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma. … VEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma
JB991
go.drugbank.com/drugs/DB05081ExperimentalIn addition a closely related cyclopentenone prostaglandin analogue has been shown to exert marked anti-inflammatory effect in vivo in an animal model. The drug will be applied topically on the skin. … The drug exerts marked antiproliferative and pro-apoptotic effect in human keratinocytes and fibroblasts in vitro.
Volixibat
go.drugbank.com/drugs/DB13914Investigationalthe liver have been implicated in its pathogenesis[A32119]. … Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for the treatment of NASH as abnormal cholesterol metabolism and accumulation of free cholesterol in
Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigationalThe reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910] … [A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively.
Niflumic acid
go.drugbank.com/drugs/DB04552InvestigationalNiflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.
Capreomycin
go.drugbank.com/drugs/DB00314ApprovedInvestigationalCyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.